Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Scott Biller sold 3,000 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $65.00, for a total transaction of $195,000.00. Following the completion of the transaction, the insider now owns 56,059 shares in the company, valued at approximately $3,643,835. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Scott Biller also recently made the following trade(s):
- On Friday, December 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $60.79, for a total transaction of $130,455.34.
- On Wednesday, November 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $62.69, for a total transaction of $134,532.74.
Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) opened at $75.11 on Friday. Agios Pharmaceuticals Inc has a 52 week low of $39.24 and a 52 week high of $76.02.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. During the same period in the previous year, the firm posted ($1.63) earnings per share. The business’s revenue was up 26.4% compared to the same quarter last year. equities research analysts forecast that Agios Pharmaceuticals Inc will post -6.59 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of AGIO. QS Investors LLC bought a new stake in Agios Pharmaceuticals in the second quarter valued at $144,000. Cubist Systematic Strategies LLC increased its stake in Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in Agios Pharmaceuticals in the third quarter valued at $225,000. S&CO Inc. bought a new stake in Agios Pharmaceuticals in the third quarter valued at $227,000. Finally, Macquarie Group Ltd. bought a new stake in Agios Pharmaceuticals in the third quarter valued at $245,000. 93.79% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on the stock. SunTrust Banks restated a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. JPMorgan Chase & Co. restated a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Credit Suisse Group boosted their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Finally, Oppenheimer restated a “buy” rating and issued a $83.00 target price on shares of Agios Pharmaceuticals in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $75.00.
COPYRIGHT VIOLATION NOTICE: “Scott Biller Sells 3,000 Shares of Agios Pharmaceuticals Inc (AGIO) Stock” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/scott-biller-sells-3000-shares-of-agios-pharmaceuticals-inc-agio-stock.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.